MDCG 2023-3 Rev 1 released

    MDCG 2023-3 Rev 1 released

    Regulatory Affairs

    Friday, 15 November 2024

    person-image

    Kirsten Van Garsse, Authorized Representative Director & Regulatory Affairs Manager IVD

    share-iconshare-icon-mob Share

    X (Twitter) icon\ \ X (Twitter) LinkedIn icon\ \ LinkedIn WhatsApp icon\ \ WhatsApp Copy link icon\ \ Copy link Mail icon\ \ Mail

    On November 11th, 2024, the Medical Device Coordination Group (MDCG) released its first revision (MDCG 2023-3 Rev 1) of the questions and Answers on vigilance terms and concepts as outlined in the Regulation (EU) 2017/745 and Regulation (EU) 2017/746. MDCG 2023-3 provides a clearer framework for key terms and concepts essential to implementing the vigilance requirements under EU Regulations (MDR 2017/745 and IVDR 2017/746). Aimed at competent authorities, economic operators, and other stakeholders, the document harmonizes definitions for effective regulatory compliance.

    RA update - MDCG 2023-3 Rev 1 releasedQuestions and Answers on vigilance terms and concepts as outlined in the Regulation (EU) 2017/745 and Regulation (EU) 2017/746.

    Some key takeaways from the revised MDCG

    The updated MDCG 2023-3 guidance expands its scope to include the IVDR, alongside general clarifications to support stakeholders in implementing vigilance requirements.

    Some key updates include:

    • Enhanced Definitions: A new table clearly distinguishes ‘incident’ and ‘serious incident’ under both the MDR and IVDR.
    • Flowchart Update: The decision-making flowchart has been revised to explicitly reference both regulations.
    • Targeted Examples: Examples specific to IVDR have been added, alongside new cases applicable to both MDR and IVDR.
    • Additional Questions: New questions have been included to address practical considerations across both regulatory frameworks.

    These updates aim to ensure consistent interpretation and effective application of vigilance requirements under the MDR and IVDR.

    What does it mean to you?

    This new revision is key for Medical Device and IVD manufacturers to ensure your vigilance procedures are aligned with the updated definitions and examples. In addition the revision is useful for economic operators and other stakeholders to familiarize themselves with the updated guidance to remain compliant, especially when reporting incidents or conducting post-market surveillance.

    drug safety monitoring

    Discover more expert content

    Previous

    Regulatory Affairs

    27 May 2024

    New MDCG & Stakeholders Survey on MDR/IVDR Certifications and Applications Released by Notified Bodies

    On May 17th, 2024, the European Commission released the survey results of the 8th Notified Body...

    Read more

    Regulatory Affairs

    17 Dec 2025

    MHRA publishes new IVD Roadmap

    The roadmap sets out broad timelines and planned activities across three key themes:

    Read more

    Regulatory Affairs

    6 Nov 2024

    MDCG 2024-13 and MDCG 2022-5 Rev 1 released

    On October 29th, 2024, the Medical Device Coordination Group (MDCG) released a new guidance (MDCG...

    Read more

    Regulatory Affairs

    22 Apr 2024

    New MDCG Guidance on Safety Reporting for Performance Studies of In Vitro Diagnostic Medical Devices under EU Regulation 2017/746 Released

    On April 15th, 2024, the Medical Device Coordination Group (MDCG) released a new guidance document...

    Read more

    Regulatory Affairs

    15 Mar 2024

    New MDCG Guidance Released: Detailed Instructions for Clinical Investigation Plans in Medical Device Studies

    New MDCG Guidance documents released: Guidance on the content of the Clinical Investigation Plan...

    Read more

    Regulatory Affairs

    27 May 2024

    New MDCG & Stakeholders Survey on MDR/IVDR Certifications and Applications Released by Notified Bodies

    On May 17th, 2024, the European Commission released the survey results of the 8th Notified Body...

    Read more

    Regulatory Affairs

    17 Dec 2025

    MHRA publishes new IVD Roadmap

    The roadmap sets out broad timelines and planned activities across three key themes:

    Read more

    Regulatory Affairs

    6 Nov 2024

    MDCG 2024-13 and MDCG 2022-5 Rev 1 released

    On October 29th, 2024, the Medical Device Coordination Group (MDCG) released a new guidance (MDCG...

    Read more

    Regulatory Affairs

    22 Apr 2024

    New MDCG Guidance on Safety Reporting for Performance Studies of In Vitro Diagnostic Medical Devices under EU Regulation 2017/746 Released

    On April 15th, 2024, the Medical Device Coordination Group (MDCG) released a new guidance document...

    Read more

    Regulatory Affairs

    15 Mar 2024

    New MDCG Guidance Released: Detailed Instructions for Clinical Investigation Plans in Medical Device Studies

    New MDCG Guidance documents released: Guidance on the content of the Clinical Investigation Plan...

    Read more

    Regulatory Affairs

    27 May 2024

    New MDCG & Stakeholders Survey on MDR/IVDR Certifications and Applications Released by Notified Bodies

    On May 17th, 2024, the European Commission released the survey results of the 8th Notified Body...

    Read more

    Regulatory Affairs

    17 Dec 2025

    MHRA publishes new IVD Roadmap

    The roadmap sets out broad timelines and planned activities across three key themes:

    Read more

    Next

    • 1
    • 2
    • 3

    Discover all

    Stay ahead in life sciences

    Keeping up with the fast-paced life sciences industry doesn’t have to be overwhelming.

    Our newsletter delivers the latest insights, industry updates, and expert content directly to your inbox, helping you stay informed and make smarter decisions.

    Subscribe to our newsletter

    Circles-banner-short

    Twitter Widget Iframe